Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in four clinical trials including the pivotal Phase 2 HORIZON trial and the ongoing Phase 3 OCEAN trial, the Phase 1/2 combination trial ANCHOR and the Phase 2 Trial BRIDGE.
The company plans for filing a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma based on data from the HORIZON study. The company targets to submit the application in end of the first quarter of 2020.
Oncopeptides’ operates from the headquarters in Stockholm, Sweden, and from its US office in Mountain View, California. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.